Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)

Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide

(2014) Manthena V. S. Varma et al.   AAPS Journal

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin

(2014) Thomayant Prueksaritanont et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved

(2014) Rui Li et al.   CLINICAL PHARMACOKINETICS

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration

(2014) Guillaume Baneyx et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

In vitroandin vivoapproaches to characterize transporter-mediated disposition in drug discovery

(2014) Bo Feng et al.   Expert Opinion on Drug Discovery

Practical permeability-based hepatic clearance classification system (HepCCS) in drug discovery

(2014) Peter W Fan et al.   Future Medicinal Chemistry

Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models

(2014) Franco Lombardo et al.   JOURNAL OF MEDICINAL CHEMISTRY

A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling

(2014) Rui Li et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3

(2014) Jianghao Ye et al.   Pharmacological Reports

Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine

(2013) Fabian Müller et al.   BIOCHEMICAL PHARMACOLOGY

Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism

(2013) Y Tomita et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

(2013) Hugh A Barton et al.   Expert Opinion on Drug Metabolism & Toxicology

Transporter biology in drug approval: Regulatory aspects

(2013) Kazuya Maeda et al.   MOLECULAR ASPECTS OF MEDICINE

Applications of CYP450 Testing in the Clinical Setting

(2013) C. F. Samer et al.   Molecular Diagnosis & Therapy

MDR1 and OAT1/OAT3 Mediate the Drug-Drug Interaction between Puerarin and Methotrexate

(2013) Qi Liu et al.   PHARMACEUTICAL RESEARCH

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

(2013) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4

(2013) Azza A.K. El-Sheikh et al.   Translational Research

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

(2012) Christopher A. Lipinski et al.   ADVANCED DRUG DELIVERY REVIEWS

Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms

(2012) Kenta Yoshida et al.   Annual Review of Pharmacology and Toxicology

Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions

(2012) Gian Camenisch et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption

(2012) Yoshihisa Shitara et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

(2012) R Elsby et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients

(2012) Xiao-Man Chu et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3

(2012) Jianghao Ye et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

(2012) Yurong Lai et al.   Expert Opinion on Drug Metabolism & Toxicology

In silico Prediction of Total Human Plasma Clearance

(2012) Giuliano Berellini et al.   Journal of Chemical Information and Modeling

pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery

(2012) Manthena V. Varma et al.   MOLECULAR PHARMACEUTICS

Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3

(2012) Keiji Shimizu et al.   NUCLEAR MEDICINE AND BIOLOGY

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

(2012) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine

(2012) Chang-Ik Choi et al.   XENOBIOTICA

BDDCS Applied to Over 900 Drugs

(2011) Leslie Z. Benet et al.   AAPS Journal

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

(2011) Hannah M. Jones et al.   CLINICAL PHARMACOKINETICS

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

(2011) K Maeda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Targeting Intestinal Transporters for Optimizing Oral Drug Absorption

(2011) Manthena V. Varma et al.   CURRENT DRUG METABOLISM

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

(2011) Paul Morgan et al.   DRUG DISCOVERY TODAY

Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption

(2011) S. W. Paine et al.   DRUG METABOLISM AND DISPOSITION

Phase II failures: 2008–2010

(2011) John Arrowsmith   NATURE REVIEWS DRUG DISCOVERY

The BCS, BDDCS, and Regulatory Guidances

(2011) Mei-Ling Chen et al.   PHARMACEUTICAL RESEARCH

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

(2011) Katherine S. Fenner et al.   XENOBIOTICA

Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19

(2010) Shizuo Narimatsu et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation

(2010) R. S. Foti et al.   DRUG METABOLISM AND DISPOSITION

Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties

(2010) R. R. Gupta et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters

(2010) Hiroyuki Kusuhara et al.   DRUG METABOLISM REVIEWS

Sandwich-cultured hepatocytes: anin vitromodel to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity

(2010) Brandon Swift* et al.   DRUG METABOLISM REVIEWS

Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state

(2010) Bo Feng et al.   Expert Opinion on Drug Metabolism & Toxicology

Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

(2010) Manthena V. S. Varma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Increased Affinity to Canalicular P-gp via Formation of Lipophilic Ion-Pair Complexes with Endogenous Bile Salts is Associated with Mw Threshold in Hepatobiliary Excretion of Quaternary Ammonium Compounds

(2010) Im-Sook Song et al.   PHARMACEUTICAL RESEARCH

Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)

(2009) Yash A. Gandhi et al.   AAPS Journal

Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships

(2009) Xinning Yang et al.   AAPS Journal

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase

(2009) David J. Greenblatt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Impact of OATP transporters on pharmacokinetics

(2009) A Kalliokoski et al.   BRITISH JOURNAL OF PHARMACOLOGY

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

(2009) Yi-Jing He et al.   CLINICA CHIMICA ACTA

In Silico Prediction of Biliary Excretion of Drugs in Rats Based on Physicochemical Properties

(2009) G. Luo et al.   DRUG METABOLISM AND DISPOSITION

Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans

(2009) T. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion

(2009) Yurong Lai   Expert Opinion on Drug Metabolism & Toxicology

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

(2009) Ichiro Ieiri et al.   Expert Opinion on Drug Metabolism & Toxicology

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

(2009) Natilie A. Hosea et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Physicochemical Determinants of Human Renal Clearance

(2009) Manthena V. S. Varma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

(2009) Agnès Poirier et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Interplay of Transporters and Enzymes in Drug and Metabolite Processing

(2009) K. Sandy Pang et al.   MOLECULAR PHARMACEUTICS

The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs

(2009) Sarah Shugarts et al.   PHARMACEUTICAL RESEARCH

Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs

(2009) Pär Matsson et al.   PHARMACEUTICAL RESEARCH

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

(2009) S. G. Aller et al.   SCIENCE

Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism

(2008) A Kalliokoski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

(2008) HX Zheng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Involvement of Multidrug Resistance-Associated Protein 2 (Abcc2) in Molecular Weight-Dependent Biliary Excretion of  -Lactam Antibiotics

(2008) Y. Kato et al.   DRUG METABOLISM AND DISPOSITION

Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

(2008) R. S. Obach et al.   DRUG METABOLISM AND DISPOSITION

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

Structural Requirements for Drug Inhibition of the Liver Specific Human Organic Cation Transport Protein 1

(2008) Gustav Ahlin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

(2008) T. Watanabe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation

(2008) Urban Fagerholm   JOURNAL OF PHARMACY AND PHARMACOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Transport Mechanisms of Carnosine in SKPT Cells: Contribution of Apical and Basolateral Membrane Transporters

(2008) Dilara Jappar et al.   PHARMACEUTICAL RESEARCH

The Use of BDDCS in Classifying the Permeability of Marketed Drugs

(2008) Leslie Z. Benet et al.   PHARMACEUTICAL RESEARCH

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

(2007) Joseph M. Custodio et al.   ADVANCED DRUG DELIVERY REVIEWS

Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

(2007) H. Jeong et al.   XENOBIOTICA